Ionis Pharmaceuticals (IONS) director Hayden bought 15,000 shares for $478K at $31.86
Insider transactions reported
Michael R Hayden (director at Ionis Pharmaceuticals Inc., IONS) reported that they bought 15,000 shares for $478K at $31.86 on May 1, 2025. After these transactions the filing shows 50,219 shares held directly.
- Reporting person
- Hayden Michael R
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| May 1, 2025 | Open-market purchase (P) | Common Stock1 | +15,000 | $31.86 | $478K | 50,219 direct |
Holdings before and after
- Common Stock: 35,219 to 50,219 direct
Other positions listed
- Common Stock: 2,000 indirect, by Spouse
Footnotes from the filing
- 1. The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $31.50 to $32.09 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) on this Form 4.
- 2. These securities are held by Genworks 2 Consulting, Inc. ( Genworks 2 ). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2.
Transaction codes in this filing
- Open-market purchase:
- Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
FAQ
What did Hayden report in this IONS Form 4?
Michael R Hayden (director at Ionis Pharmaceuticals Inc., IONS) reported that they bought 15,000 shares for $478K at $31.86 on May 1, 2025. After these transactions the filing shows 50,219 shares held directly.
How many IONS shares does Hayden hold after this filing?
The filing shows 50,219 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code P mean on an SEC Form 4?
Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
Ask Ellis, your AI research assistant, about this story
Historical context for IONS
Earlier insider filings at IONS
- Apr 17, 2025EVP, Corp and Development Ops Birchler Brian converted options into 1,875 shares and sold $19,292 worth of shares (680 units at $28.37), increasing direct ownership by 2% to 56,660 units (SEC Form 4)
- Apr 17, 2025EVP, Chf GL Pdt Str Ofcr Jenne Kyle sold $85,534 worth of shares (3,016 units at $28.36) and converted options into 12,226 shares, increasing direct ownership by 463% to 11,199 units (SEC Form 4)
- Apr 17, 2025EVP, Chief Business Officer Baroldi Joseph converted options into 10,837 shares and sold $111,555 worth of shares (3,928 units at $28.40), increasing direct ownership by 28% to 31,926 units (SEC Form 4)
- Mar 13, 2025Chief Executive Officer Monia Brett P sold $4,525 worth of shares (140 units at $32.32), decreasing direct ownership by 0.08% to 180,980 units (SEC Form 4)
- Mar 4, 2025EVP Research Swayze Eric acquired $11,708 worth of shares (415 units at $28.21), increasing direct ownership by 0.86% to 48,432 units (SEC Form 4)
Keep researching IONS
- IONS insider tradesEvery buy and sale reported by Ionis Pharmaceuticals Inc. officers, directors and large holders.
- What is Insider buying?Purchases of a company's stock by its officers, directors or 10% holders, reported to the SEC on Form 4 and watched as a signal of insider confidence.
- How to track insider buyingInsider buying is tracked through SEC Form 4 code P filings. Learn how to find open-market purchases, spot cluster buys and judge which insider trades carry real signal.
- Insider trading trackerThe latest insider buys and sales across every stock.
- IONS earnings historyPast Ionis Pharmaceuticals Inc. earnings releases, newest first.
- IONS financial statementsRevenue, profit, cash flow and balance sheet from Ionis Pharmaceuticals Inc.'s SEC filings.
Our reporting on IONS
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Follow IONS and get a push notification the moment its next story breaks.
Watch IONS for work, on its IR, comms or brand team or at an agency? Send every IONS item and its competitors' to your team's Slack or Teams.
